Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:FTLFNASDAQ:GLSINYSE:HEXONASDAQ:TARA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFTLFFitLife Brands$13.32-2.3%$14.27$9.83▼$17.75$128M0.8117,529 shs8,451 shsGLSIGreenwich LifeSciences$8.90-0.2%$9.59$8.06▼$18.15$119.25M1.6946,134 shs33,040 shsHEXOHEXO$0.71+2.5%$0.87$0.66▼$3.84$31.24M1.35880,508 shs305,500 shsTARAProtara Therapeutics$3.05+2.3%$3.41$1.60▼$10.48$114.97M1.34774,705 shs321,242 shs20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFTLFFitLife Brands-2.27%-4.86%-4.17%-1.19%-3.79%GLSIGreenwich LifeSciences-0.22%-3.26%-8.53%-19.89%-44.27%HEXOHEXO0.00%0.00%0.00%0.00%0.00%TARAProtara Therapeutics+2.35%-2.87%-6.15%-33.70%+30.34%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationFTLFFitLife Brands4.1689 of 5 stars3.73.00.00.01.93.33.1GLSIGreenwich LifeSciences1.9789 of 5 stars3.51.00.00.00.03.30.0HEXOHEXON/AN/AN/AN/AN/AN/AN/AN/ATARAProtara Therapeutics2.344 of 5 stars3.62.00.00.02.90.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceFTLFFitLife Brands 3.33Buy$20.5053.90% UpsideGLSIGreenwich LifeSciences 3.00Buy$39.00338.20% UpsideHEXOHEXO 0.00N/AN/AN/ATARAProtara Therapeutics 3.14Buy$20.50572.13% UpsideCurrent Analyst Ratings BreakdownLatest HEXO, FTLF, GLSI, and TARA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/22/2025TARAProtara TherapeuticsJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy$21.004/28/2025TARAProtara TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$23.00 ➝ $23.004/21/2025GLSIGreenwich LifeSciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$38.00 ➝ $39.004/16/2025TARAProtara TherapeuticsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageSector Outperform$12.00(Data available from 6/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookFTLFFitLife Brands$64.47M1.94$0.99 per share13.45$3.93 per share3.39GLSIGreenwich LifeSciencesN/AN/AN/AN/A$0.19 per shareN/AHEXOHEXO$146.20M0.21N/AN/A$2.44 per share0.29TARAProtara TherapeuticsN/AN/AN/AN/A$4.77 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateFTLFFitLife Brands$8.98M$0.8415.8612.11N/A13.85%25.59%15.26%N/AGLSIGreenwich LifeSciences-$15.79M-$1.26N/AN/AN/AN/A-450.87%-333.18%8/12/2025 (Estimated)HEXOHEXO-$845.90M-$5.21N/AN/AN/A-235.33%-74.04%-32.51%N/ATARAProtara Therapeutics-$44.60M-$1.72N/AN/AN/AN/A-36.37%-33.29%8/5/2025 (Estimated)Latest HEXO, FTLF, GLSI, and TARA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/20/2025Q1 2025GLSIGreenwich LifeSciences-$0.24-$0.25-$0.01-$0.25N/AN/A5/15/2025Q1 2025FTLFFitLife Brands$0.24$0.20-$0.04$0.20N/AN/A5/8/2025Q1 2025TARAProtara Therapeutics-$0.47-$0.29+$0.18-$0.29N/AN/A4/15/2025Q4 2024GLSIGreenwich LifeSciences-$0.21-$0.61-$0.40-$0.61N/AN/A3/27/2025Q4 2024FTLFFitLife Brands$0.22$0.21-$0.01N/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthFTLFFitLife BrandsN/AN/AN/AN/AN/AGLSIGreenwich LifeSciencesN/AN/AN/AN/AN/AHEXOHEXON/AN/AN/AN/AN/ATARAProtara TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioFTLFFitLife Brands0.191.640.72GLSIGreenwich LifeSciencesN/A1.911.91HEXOHEXO0.010.410.24TARAProtara TherapeuticsN/A18.0318.03Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipFTLFFitLife Brands2.32%GLSIGreenwich LifeSciences4.16%HEXOHEXO7.78%TARAProtara Therapeutics38.13%Insider OwnershipCompanyInsider OwnershipFTLFFitLife Brands61.30%GLSIGreenwich LifeSciences51.67%HEXOHEXO4.69%TARAProtara Therapeutics8.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableFTLFFitLife Brands209.39 million3.63 millionNot OptionableGLSIGreenwich LifeSciences313.37 million6.46 millionNot OptionableHEXOHEXO1,27744.00 million41.93 millionOptionableTARAProtara Therapeutics3038.58 million35.34 millionOptionableHEXO, FTLF, GLSI, and TARA HeadlinesRecent News About These CompaniesProtara Therapeutics: Marching On To A Hopefully Eventful Back Half Of 2025June 14, 2025 | seekingalpha.comTwo Sigma Investments LP Cuts Stock Holdings in Protara Therapeutics, Inc. (NASDAQ:TARA)June 14, 2025 | marketbeat.comCantor Fitzgerald Forecasts TARA FY2026 EarningsJune 11, 2025 | americanbankingnews.comAnalysts Set Expectations for TARA FY2026 EarningsJune 10, 2025 | marketbeat.comChutes & Ladders—Protara gears up for next steps with commercial proJune 7, 2025 | fiercebiotech.comProtara Therapeutics, Inc. (NASDAQ:TARA) Position Increased by Bank of America Corp DEJune 7, 2025 | marketbeat.comProtara Therapeutics, Inc. (NASDAQ:TARA) Given Average Recommendation of "Buy" by AnalystsJune 5, 2025 | marketbeat.comThe Escalator: Digitas Health, Bristol Myers Squibb, Inizio Evoke and moreJune 4, 2025 | mmm-online.comProtara Therapeutics names new Chief Commercial OfficerJune 4, 2025 | investing.comMillennium Management LLC Purchases 357,051 Shares of Protara Therapeutics, Inc. (NASDAQ:TARA)June 3, 2025 | marketbeat.comProtara Therapeutics Announces Appointment of William Conkling as Chief Commercial OfficerJune 2, 2025 | globenewswire.comToronto Dominion Bank Acquires New Stake in Protara Therapeutics, Inc. (NASDAQ:TARA)May 30, 2025 | marketbeat.comProtara Therapeutics (NASDAQ:TARA) Earns Buy Rating from Analysts at Jones TradingMay 24, 2025 | marketbeat.comBNP Paribas Financial Markets Purchases Shares of 151,906 Protara Therapeutics, Inc. (NASDAQ:TARA)May 24, 2025 | marketbeat.comJones Trading Initiates Coverage of Protara Therapeutics (TARA) with Buy RecommendationMay 23, 2025 | msn.comToronto Dominion Bank Takes Position in Protara Therapeutics, Inc. (NASDAQ:TARA)May 23, 2025 | marketbeat.comRichard Levy Spends US$64k On Protara Therapeutics StockMay 22, 2025 | finance.yahoo.comVelan Capital Investment Management LP Buys 1,005,000 Shares of Protara Therapeutics, Inc. (NASDAQ:TARA)May 21, 2025 | marketbeat.comWith 73% ownership, Protara Therapeutics, Inc. (NASDAQ:TARA) boasts of strong institutional backingMay 16, 2025 | finance.yahoo.comProtara Therapeutics to Participate in Upcoming Investor ConferencesMay 13, 2025 | globenewswire.comProtara Therapeutics Reports Q1 2025 Financial ResultsMay 11, 2025 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeHEXO, FTLF, GLSI, and TARA Company DescriptionsFitLife Brands NASDAQ:FTLF$13.32 -0.31 (-2.27%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$13.37 +0.05 (+0.38%) As of 06/20/2025 07:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.FitLife Brands, Inc. provides nutritional supplements for health-conscious consumers in the United States and internationally. The company provides weight loss, sports nutrition, and general health products; sports nutrition products; weight loss and sports nutrition products; sports nutrition and general wellness formulations with an emphasis on natural, vegan, and organic ingredients; and male health and weight loss products, as well as other diet, health, and sports nutrition supplements and related products; and value-oriented sports nutrition and weight loss products. It offers MRC products which includes general health supplements; and natural skincare and beauty products. In addition, it markets its products under the brand names of NDS Nutrition, PMD Sports, SirenLabs, CoreActive, Nutrology, Metis Nutrition, iSatori, BioGenetic Laboratories, Energize, Dr. Tobias, All-Natural Advice, and Maritime Naturals through franchised stores, as well as through retail locations, which include specialty, mass, and online. The company was formerly known as Bond Laboratories, Inc. and changed its name to FitLife Brands, Inc. in September 2013. FitLife Brands, Inc. was incorporated in 2005 and is headquartered in Omaha, Nebraska.Greenwich LifeSciences NASDAQ:GLSI$8.90 -0.02 (-0.22%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$8.88 -0.03 (-0.28%) As of 06/20/2025 06:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.HEXO NYSE:HEXOHEXO Corp., together with its subsidiaries, produces, markets, and sells cannabis in Canada. The company offers its adult-use and medical products under the HEXO brand name. It also provides cannabis beverages under the Little Victory, House of Terpenes, Mollo, Veryvell, and XMG brands; and cannabis products under UP Cannabis, Original Stash, and Up brand names. It has a strategic alliance with Tilray Brands, Inc. The company was formerly known as The Hydropothecary Corporation and changed its name to HEXO Corp. in August 2018. HEXO Corp. was founded in 2013 and is headquartered in Gatineau, Canada. As of June 22, 2023, HEXO Corp. operates as a subsidiary of Tilray Brands, Inc.Protara Therapeutics NASDAQ:TARA$3.05 +0.07 (+2.35%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$3.06 +0.01 (+0.16%) As of 06/20/2025 07:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy that is in Phase II clinical trial for patients receiving parenteral nutrition. The company is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New All-Time Highs Coming for Broadcom? Wall Street Says Yes Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer 3 Reasons AMD Could Be the Hottest Stock of the Summer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Robinhood Director Sells Millions, But HOOD Stock Eyes Gains Coinbase Stock Pops as Senate Passes GENIUS Stablecoin Bill Overheated Market? Analysts Watch These Red Flags Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
